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The pathologic assessment of tumours is central to the diag-
nosis and staging of cancer. According to the American Joint
Committee on Cancer, use of the TNM system of staging is
predicated on the histologic confirmation of cancer, and the
TNM system itself uses all available pathologic data, includ-
ing local extent of disease, involvement of regional lymph
nodes and presence of metastases (International Union
Against Cancer, 1987; American Joint Committee on Cancer,
1992). In many cancers the histologic type, histologic grade
or other histologic assessments influence the treatment of the
patient.
Some pathology assessments, for example presence of
adenocarcinoma, are readily verified on repeated assessments
by the same observer and on assessments by other observers.
Others, such as lymphatic invasion in breast carcinoma, are
not (Lee et al., 1986). Reasons for the lack of reproducibility
of assessments include differences between pathologists in
their definitions of the same terms, differences in the nomen-
clature that they use, unusual histologic patterns in a slide,
difficult visualisation of a slide and unfamiliarity with the
method of assessment. When lack of reproducibility occurs,
the problem is often exacerbated by the lack of a gold
standard, i.e. method that is widely accepted as yielding the
best knowledge available, to which the assessments can be
referred.
Doubts regarding the reproducibility of a pathologic
assessment motivate the use of pathology review in cancer
research studies. There are two main types of pathology
review, distinguished by their goals. The first type, which we
will call an observer agreement study, aims to quantify the
reproducibility of a new assessment or of an assessment
whose reproducibility is not well known. Such reviews may
be designed to investigate reproducibility between patho-
logists, within pathologists, or both. They are conducted as
stand-alone studies or as sub-studies of a larger research
project. An example of a stand-alone study is the investiga-
tion of histological grading of bladder tumours by Ooms
(1985). An example of a sub-study is the investigation of
dysplasia in normal-looking urothelium of patients with
superficial bladder cancer (Richards et al., 1991). These
reviews are best carried out early in the development of a
new pathological assessment, since establishing the level of
reproducibility is needed for an assessment to be used with
confidence.
The second type of pathology review, which we call a
reference panel review, is linked to a specific cancer research
study in which a pathology assessment has a central role.
This type of review has the narrower objective of obtaining a
definitive assessment for each individual in the associated
study. The objective is commonly achieved by appointing a
review panel of one or more expert pathologists. When the
panel has more than one member a 'consensus' between the
panel members is required to provide the definitive assess-
ment. This type of review is often used to check on the
histological diagnosis of patients entering clinical trials, pros-
pective follow-up studies, or case-control studies. See, for
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example, the Eastern Cooperative Oncology Group's pros-
pective study of 432 patients with hepatocellular carcinoma
(Falkson et al., 1988).
In this editorial we will discuss some of the principal issues
in design and analysis of these studies, noting that there are
some important differences between these for the two types
of review outlined above. First, we discuss pathology
observer agreement studies.
Observer agreement studies
There is a large statistical literature on the analysis of
observer agreement studies but little has been written on their
design. As mentioned earlier, the primary aim of observer
agreement studies is to quantify the reproducibility of an
assessment. Many different summary measures of the level of
agreement between observers have been proposed and dis-
cussed. These summary measures necessarily depend upon
the type of assessment. Landis and Koch (1975a; 1975b) have
reviewed these extensively, discussing assessments that are
continuous (such as tumour size), ordinal (stage of disease),
nominal (histologic sub-type) and binary (presence or
absence of a pathologic feature). The two summary measures
that are most commonly used in reporting pathology
observer agreement studies are the correlation coefficient for
continuous assessments and the kappa statistic for nominal
or binary assessments. These measures yield a number
between - I and + 1 where a score of + 1 indicates perfect
agreement, zero indicates the level of agreement that would
be expected by chance alone, and a minus score indicates less
agreement than that expected by chance. While investigators
have developed ad hoc rules for interpreting these scores (e.g.
for the kappa statistic, less than 0.4 represents poor agree-
ment, 0.4 to 0.75 represents fair agreement, and greater than
0.75 excellent agreement (Landis & Koch, 1973)), they do not
represent quantities that can be clearly understood and are
often used wrongly (Maclure & Willett, 1987; Bland & Alt-
man, 1986).
As an alternative, pairwise comparisons of observers can
be described using quite simple measures that carry an
intuitive meaning. For continuous assessments one may pres-
ent the mean and standard deviation of the paired differences
between any two observers, as suggested by Bland and Alt-
man (1986). The mean gives an appreciation of whether one
observer tends to score higher than the other. The standard
deviation gives an appreciation of how discordant are the
observers' scores having adjusted for any overall difference in
level of scoring. For binary data, the proportion of concor-
dant assessments (Rogot & Goldberg, 1966) made by two
observers is the most elementary measure and has much to
recommend it. Since the number of pathologists participating
in any one observer agreement study will usually be fewer
than ten (see below), such pairwise comparisons will usually
be both feasible to present and informative.
An important design issue is the selection of and number
of pathologists who take part in the review. The aim of the
review must be clearly understood to make an appropriate
choice of pathologists. A crucial question is whether one
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wishes to extrapolate the results of the review to a broad
group of pathologists or whether one is content to limit
conclusions to the group of pathologists who take part. If
one wishes to extrapolate, then one will need to take steps
(such as random sampling) to ensure that the pathologists
chosen are representative of the broader group. For example,
the reproducibility of diagnosing rhabdomyosarcoma may be
quite different among a group of experts in soft-tissue sar-
comas from among a group of general pathologists; therefore
for reliable extrapolation to the broader group one needs to
include general pathologists in the study. Some reviews
involve internationally renowned experts and are limited to
quantifying reproducibility among the group selected for the
study. Such reviews are useful if poor reproducibility is dem-
onstrated, as reproducibility is likely to be even worse
amongst those who are less expert; but a result indicating
excellent reproducibility could hardly be extended to a
broader group. On the other hand, demonstrating excellent
reproducibility would at least show what is achievable, and
would also enhance confidence in the assessments of any one
of the expert pathologists in the study. Such a result would
then justify the choice of one of the group as a reference
pathologist for a research project in that cancer.
When extrapolating to a broader group, the number of
pathologists chosen is important, since a very small number
may not guarantee sufficient representation of the broader
group: unfortunately, we know of no detailed numerical advice
that has been published on this mater. An extreme deviant
from the usual design involving a few observers is the study
reported by Owens et al. (1978) who tested the consistency of
ratings according to the ASA Physical Status Classification
by sending a questionnaire to 304 anesthesiologists. However,
pathology observer agreement studies with more than ten
pathologists are unlikely to be logistically feasible, bearing in
mind the requirement that each pathologist independently
assess the same set of tens or hundreds of slides. Further
work is needed to clarify the degree of confidence that one
could place in extrapolation from studies with ten or fewer
pathologists taking part. In the 'experts' study, however, the
number of pathologists is less of a statistical matter and may
be dictated by matters of politics (for example, who is
counted as an international expert!), cost and convenience.
Another important issue concerns replicate (or repeat)
assessments of the same slides. Without replicate assessments
one may quantify, as described, the level of disagreement
between pathologists on a single assessment, but one cannot
know how much of that disagreement is due to inconsistency
of assessment by individual pathologists (intra-observer
variation) and how much is due to real differences of percep-
tion among pathologists (inter-observer variation) (Freedman
et al., 1993). Such information can be essential if, following
the review, one wishes to take action to reduce the disagree-
ment. Some pathologists may be more inconsistent than
others in their assessments, or there may be a tendency for
some pathologists towards allotting a certain category more
often than their colleagues. Baker et al. (1991) present an
analysis of intra- and inter- pathologist variation found in
the study reported by Richards et al. (1991).
If one wishes to include in the study design replicate
assessments of the same material by pathologists, then these
assessments should be made independently. Two practical
steps will help to meet this requirement. Firstly, at the repeat
examination the slides should not carry an identification
mark that would enable the pathologist to recognise the slide
from the first examination and the slides should be presented
in a different order (that is, the pathologist should be blinded
to the patient's identity). Secondly, the period between
examinations should be long enough for the pathologist to
forget the appearance of individual slides from the first
examination and his or her corresponding assessments.
A third issue concerns the selection and number of patients
to be included. The principles behind selection of the patients
are similar to those behind selection of the pathologists.
Since one would like to generalise the results to a broader
group of patients those included should represent the broader
group. Thus one may wish to avoid entering only patients
who are referred to a center that specialises in the diagnosis
and treatment of unusual forms of the disease in question.
Entry criteria should be defined as carefully as for a clinical
trial, since these criteria will clarify the nature of the broader
group to which results may be extrapolated.
How many patients should be examined in a observer
agreement study? The larger the number of patients the more
precisely one may estimate the level of agreement. Freedman
et al. (1993) present tables for studies with or without rep-
licate assessments. The numbers depend upon the anticipated
level of agreement, and, of course, upon the precision with
which one wishes to estimate the reproducibility. Studies
without replicates, being less ambitious, in that they do not
aim to estimate separately intra- and inter- pathologist com-
ponents of variation, require fewer patients. Neverthless, for
reasonable precision, (that is, a 90% confidence interval
width of 0.10 to 0.15 for the proportion of disagreement)
these studies often require between 50 and 250 patients. For
example, if the proportion of disagreement were really 0.15
and one required its estimate to have a 90% confidence
interval width of 0.10, then 138 patients would be needed.
However, it is usual to see studies with fewer than 50 patients
being reported in the literature.
For studies with replicates, between 100 and 600 patients
are often required. For example, Richards et al. (1991),
referred to earlier, reported a study of the assessment of
dysplasia in the normal-looking urothelium of patients with
superficial bladder cancer. Five pathologists specialising in
urology examined 100 histological slides, each from a
different patient. Some months later 30 of these slides were
sent for blind reassessment by each pathologist. These
numbers were chosen for practical reasons with only infor-
mal consideration given to statistical precision. The methods
of Freedman et al. (1993) indicate that, for reasonable
precision in the separate estimation of within- and between-
pathologist agreement, 170 patients should have been
included, with each assessed twice by each pathologist.
Within a group of patients, there may be subgroups that
are more difficult to assess. For example, in a review of
nonlymphoblastic lymphomas (Wilson et al., 1987), consen-
sus agreement was achieved in 67% overall, but was 82% for
cases of Burkitt's lymphoma and 54% for non-Burkitt's lym-
phoma. A useful adjunct to pathology review is therefore to
record characteristics of patients that may be related to the
reproducibility of an assessment. Later analysis may then
reveal useful information regarding factors that can influence
the difficulty of this assessment.
There are a number of other questions regarding the con-
ditions under which the review is conducted. These include
the number of slides that are needed to represent adequately
the biopsied tissue of each patient, and the use of other
information about the patient that may contribute toward
the assessment. For the results of a pathology review to be
more applicable to clinical practice, a useful rule is to allow
the assessment in the review to take place under the same
conditions as usual clinical practice. However, this rule may
sometimes conffict with the need for blinding repeated assess-
ments, in which case maintaining the blind is the overriding
consideration.
Finally, Henson (1989) argues that at the end of any
observer-agreement study, the estimated level ofdisagreement
should be related to the possible clinical consequences. For
example, one should consider the proportion of patients for
whom there would be consequent disagreement on the course
of treatment.
Reference panel reviews
Design considerations relating to reference panel reviews are
very different since the aim is to reach a definitive assessment
rather than to quantify levels of agreement. The most fun-
damental issue is whether a pathology review is required at
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ing inclusion of patients with soft-tissue sarcoma (Borden et
al., 1990). Patients are entered if the local clinical centre
pathologist diagnoses soft-tissue sarcoma. Do we need a
pathology reference panel to check on the diagnosis and
declare ineligible those patients whose diagnosis is
unconfirmed? It is important to note that if the reference
panel's diagnosis were obtained after randomisation, then
eliminating the ineligibles would contravene the 'Intention to
Treat' principle, namely that one should retain all ran-
domised patients in the analysis in the groups to which they
are randomised. However, most authors regard this partic-
ular type of contravention as innocuous, since no treatment
related bias can arise. The 'Intention to Treat' issue is dis-
cussed by Lewis and Machin (1993), in another editorial of
this series.
Clearly, setting up a pathology reference panel will involve
a considerable amount of effort and expense, so we must
examine the likely impact of such a panel on the study
results. Under certain circumstances, to be discussed below, a
useful rule is the following: if p is the proportion of cases
that would be found ineligible by the pathology reference
panel, establishing a panel would yield the same benefit in
statistical power as increasing the number of patients by the
multiplicative factor
F= 1 (l-_p)2.
Thus if the trial were planned with 130 patients and the
anticipated ineligibility proportion were 0.07 (or 7%) (Wilson
et al., 1987), then establishing a panel would have the same
benefit as increasing the number to
350 =405,
(1 0.07)2
an extra 55 patients in the study. The larger the ineligibility
proportion is, the larger the benefit from a panel will be.
Conversely for small values of p, the benefits will diminish.
Some preliminary work at the beginning ofthe trial comparing
the cost of establishing a reference panel with the cost of
extending the trial to include the larger number of patients,
may often clearly reveal whether the panel is worthwile.
However, such calculations have not been reported.
The F rule rests on the assumptions that: (i) the treatments
being compared are inappropriate and equally ineffective for
the ineligible patients and (ii) the panel correctly identifies the
eligible and ineligible patients. Whether or not condition (i)
holds depends upon the nature ofthe eligibility criteria and the
treatments under study. Condition (i) is more likely to hold if
eligibility is based upon an assessment of the histologic type of
the tumour, since many treatments are specific to a histologic
type. It is less likely to hold if eligibility is based upon his-
tologic stage or grade since a treatment's effectiveness often
extends to other stages or grades. In this case the F rule could
grossly overestimate the benefit to be derived from a reference
panel. Condition (ii) is clearly impossible to check when there
is no gold standard. Reasons for doubting that condition (ii)
holds include the presence of serious disagreement among
expert pathologists, and the concem that the reference panel
would not see the total material available to the local
pathologist. The latter concern could be met, by asking the
local pathologist to send further material in cases thought by
the panel to be ineligible. If there is an appreciable rate of
errors made by the reference panel then again the F rule
overestimates the benefit of such a panel. In general, the F rule
provides a useful estimate of the maximum benefit to be
obtained from a reference panel.
The above discussion is based upon the premise that
pathology review is needed to exclude ineligible patients from
the trial. Sometimes other benefits may accrue from the panel,
such as the more accurate assessment of histologic subtypes, as
by Borden et al. (1990), for soft-tissue sarcomas. Also, some
review panels are established to assess endpoint criteria, such
as the recurrence of polyps in a polyp prevention trial. The F
rule is not always applicable to this use of review panels;
however, it is generally true that the greater the proportion of
discrepancies between the local centre assessments and the
reference panel assessments, the greater are the benefits deriv-
ing from the panel.
As mentioned before, the review panel's assessment cannot
be guaranteed correct. Considering this issue raises the ques-
tion of how many pathologists should serve on a review panel,
and the associated question of how one should define the
panel's assessment in the events of disagreement between the
members. Panel membership sizes range from one to several.
In one trial, working with a membership of one was not
successful, since the expert pathologist was later discovered to
differ widely from his peers! Again we can report no published
statistical work on the size of panel membership and the rules
for a 'consensus' assesment, aside from recent preliminary
work by Kraemer (1992) who presented a method of relating
the number of panel members to the reliability of the consen-
sus diagnosis.
In summary, the most common use of reference panels is to
check eligibility. Wolf et al. (1988) reported an analysis of a
two-tier system of review for ECOG trials of lymphomas and
Hodgkin's disease, involving local review pathologists and a
central level. They concluded that 86% of the ineligibles were
found at the first tier and that a two-tier system was unneces-
sary. This accords with our general impression that pathology
reference panels are established far more often than necessary
in multi-centre clinical trials. Moreover, using the local
pathologist's diagnosis, rather than a reference panel's diag-
nosis, as the criterion for eligibility can make the results more
generalisable to everyday clinical practice.
Summary
Pathology observer agreement studies are clearly important in
the development of new pathology assessments and in the
quality control of those assessments in common use. Setting
up such studies, and reporting and interpreting their results
requires careful thought and statistical expertise. Investigators
are advised to seek collaboration with a statistician before
embarking on these studies.
Pathology reference panel reviews in multicentre studies are
useful for checking eligibility when there is a high level of
disagreement on the eligibility criterion between local
pathologists and the reference panel members, but good agree-
ment between members of the panel. However, such situations
are uncommon.
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